{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:40:31Z","timestamp":1789742431474,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40265-025-02249-y","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:42:19Z","timestamp":1759246939000},"page":"1621-1627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mazdutide: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2249_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003","volume":"165","author":"A Novikoff","year":"2023","unstructured":"Novikoff A, Muller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165:171003.","journal-title":"Peptides"},{"key":"2249_CR2","unstructured":"Innovent Biologics. Innovent announces the NDA of mazdutide for type 2 diabetes has been accepted by the NMPA of China [media release]. 01 Aug 2024. http:\/\/www.innoventbio.com."},{"key":"2249_CR3","unstructured":"Innovent Biologics. Innovent's first New Drug Application of mazdutide for chronic weight management has been accepted by the NMPA of China [media release]. 07 Feb 2024. http:\/\/www.innoventbio.com."},{"key":"2249_CR4","unstructured":"Innovent Biologics. Mazdutide injection: Chinese prescribing information [Chinese]. 2025. https:\/\/img.innoventbio.com\/product\/W10030842001.pdf. Accessed 04 Sep 2025."},{"key":"2249_CR5","unstructured":"National Medical Products Administration. Mazdutide injection: NMPA approval notice [Chinese]. 2025. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20250627145044169.html. Accessed 04 Sep 2025."},{"key":"2249_CR6","unstructured":"Innovent Biologics. Innovent announces mazdutide received approval from China's NMPA for glycemic control in adults with type 2 diabetes [media release]. 19 Sep 2025. http:\/\/www.innoventbio.com."},{"key":"2249_CR7","unstructured":"Innovent Biologics. Innovent announces financial results for full year ended December 31, 2019 and corporate progress [media release]. 30 Mar 2020. http:\/\/www.innoventbio.com."},{"key":"2249_CR8","unstructured":"Innovent Biologics. Innovent enters a licensing agreement with Lilly to develop & commercialize a novel diabetes medicine in China [media release]. 21 Aug 2019. http:\/\/www.innoventbio.com."},{"key":"2249_CR9","doi-asserted-by":"crossref","unstructured":"Chen YY, Mezo A, Coskun T, et al. Novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice [abstract]. Diabetes. 2021;70(Suppl 1):682-P.","DOI":"10.2337\/db21-682-P"},{"issue":"22","key":"2249_CR10","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025;392(22):2215\u201325.","journal-title":"N Engl J Med"},{"key":"2249_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101691","volume":"54","author":"L Ji","year":"2022","unstructured":"Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691.","journal-title":"EClinicalMedicine"},{"key":"2249_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101088","volume":"39","author":"L Ji","year":"2021","unstructured":"Ji L, Jiang H, An P, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021;39:101088.","journal-title":"EClinicalMedicine"},{"issue":"1 Suppl","key":"2249_CR13","first-page":"S352","volume":"67","author":"SN Bhattacha","year":"2024","unstructured":"Bhattacha SN, Tham L, Li Y, et al. Mazdutide reduces body weight in adults with overweight or obesity: a multiple-dose study [abstract]. Diabetologia. 2024;67(1 Suppl):S352.","journal-title":"Diabetologia"},{"issue":"1 Suppl","key":"2249_CR14","first-page":"S357","volume":"67","author":"L Tham","year":"2024","unstructured":"Tham L, Bhattachar SN, Li Y, et al. GLP-1 and glucagon receptor agonist mazdutide improves markers of metabolic function in adults with overweight or obesity [abstract]. Diabetologia. 2024;67(1 Suppl):S357.","journal-title":"Diabetologia"},{"issue":"1","key":"2249_CR15","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","volume":"14","author":"L Ji","year":"2023","unstructured":"Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289.","journal-title":"Nat Commun"},{"issue":"1 Suppl","key":"2249_CR16","first-page":"S351","volume":"67","author":"H Jiang","year":"2024","unstructured":"Jiang H, Ji L, Zhang Y, et al. A phase 2 study of mazdutide 9 mg in Chinese adults with BMI\u226530 kg\/m2 [abstract]. Diabetologia. 2024;67(1 Suppl):S351\u20132.","journal-title":"Diabetologia"},{"key":"2249_CR17","doi-asserted-by":"crossref","unstructured":"Zhu D, Zhao J, Cai H, et al. Mazdutide vs. placebo as monotherapy in patients with type 2 diabetes (DREAMS-1) [abstract]. Diabetes. 2025;74(Suppl 1):306-OR.","DOI":"10.2337\/db25-306-OR"},{"issue":"1 Suppl","key":"2249_CR18","first-page":"S516","volume":"67","author":"L Guo","year":"2024","unstructured":"Guo L, Yang W, Dong X, et al. Mazdutide vs dulaglutide in patients with type 2 diabetes (DREAMS-2): a randomised, open-label, 28-week phase 3 trial [abstract]. Diabetologia. 2024;67(1 Suppl):S516\u20137.","journal-title":"Diabetologia"},{"issue":"12","key":"2249_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120(12):1427\u201341.","journal-title":"Cardiovasc Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02249-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:34:06Z","timestamp":1763044446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02249-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02249-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}